SRR8518128
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.660
- ANGIOGENESIS+0.540
- COAGULATION+0.510
- COMPLEMENT+0.390
- MYOGENESIS+0.380
- APICAL_JUNCTION+0.350
- TGF_BETA_SIGNALING+0.340
- UV_RESPONSE_DN+0.340
- NOTCH_SIGNALING+0.330
- INFLAMMATORY_RESPONSE+0.320
Top 10 suppressed
- MYC_TARGETS_V2-0.660
- MYC_TARGETS_V1-0.610
- E2F_TARGETS-0.550
- G2M_CHECKPOINT-0.490
- OXIDATIVE_PHOSPHORYLATION-0.370
- MTORC1_SIGNALING-0.360
- UNFOLDED_PROTEIN_RESPONSE-0.360
- CHOLESTEROL_HOMEOSTASIS-0.350
- DNA_REPAIR-0.320
- PEROXISOME-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A2-A0YD-01A-11R-A109-07 | — | A | 0.924 |
| 2 | TCGA-55-6980-01A-11R-1949-07 | — | cohortA1 | 0.920 |
| 3 | TCGA-CN-6016-01A-11R-1686-07 | — | — | 0.917 |
| 4 | SRR12475153 | — | — | 0.913 |
| 5 | TCGA-22-1000-01A-01R-A32Z-07 | — | cohortSQ1 | 0.912 |
| 6 | GSM6454745 | — | A | 0.912 |
| 7 | TCGA-78-8648-01A-11R-2403-07 | — | cohortMD2 | 0.909 |
| 8 | TCGA-AC-A3HN-01A-11R-A213-07 | — | A | 0.908 |
| 9 | SRR5088925 | — | — | 0.904 |
| 10 | TCGA-50-8459-01A-11R-2326-07 | — | cohortMD2 | 0.903 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.660 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.540 | Remibrutinib | — uncovered |
| COAGULATION | 0.510 | Binimetinib | — uncovered |
| COMPLEMENT | 0.390 | Inavolisib | — uncovered |
| MYOGENESIS | 0.380 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.350 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.340 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.340 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.330 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.320 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.270 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.260 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.250 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.250 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.230 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.230 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.210 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.210 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |